Mapping Plasma Biomarker Progression Against the Amyloid Clock

Abstract

Background: Plasma biomarkers are potential candidates for screening patients for anti‐amyloid therapies. Although early changes have been reported, the duration of Aβ‐accumulation afetr which these changes become abnormal enough to identify Aβ+ individuals has yet to be determined.